These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35968541)

  • 1. Generalizing trial evidence to target populations in non-nested designs: Applications to AIDS clinical trials.
    Li F; Buchanan AL; Cole SR
    J R Stat Soc Ser C Appl Stat; 2022 Jun; 71(3):669-697. PubMed ID: 35968541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights.
    Buchanan AL; Hudgens MG; Cole SR; Mollan KR; Sax PE; Daar ES; Adimora AA; Eron JJ; Mugavero MJ
    J R Stat Soc Ser A Stat Soc; 2018 Oct; 181(4):1193-1209. PubMed ID: 30555215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the Relation Between G-formula and Inverse Probability Weighting Estimators for Generalizing Trial Results.
    Dahabreh IJ; Robertson SE; Hernán MA
    Epidemiology; 2019 Nov; 30(6):807-812. PubMed ID: 31517670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doubly robust estimators for generalizing treatment effects on survival outcomes from randomized controlled trials to a target population.
    Lee D; Yang S; Wang X
    J Causal Inference; 2022; 10(1):415-440. PubMed ID: 37637433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doubly robust estimation of the weighted average treatment effect for a target population.
    Tao Y; Fu H
    Stat Med; 2019 Feb; 38(3):315-325. PubMed ID: 30302780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variance estimation for the average treatment effects on the treated and on the controls.
    Matsouaka RA; Liu Y; Zhou Y
    Stat Methods Med Res; 2023 Feb; 32(2):389-403. PubMed ID: 36476035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study Designs for Extending Causal Inferences From a Randomized Trial to a Target Population.
    Dahabreh IJ; Haneuse SJA; Robins JM; Robertson SE; Buchanan AL; Stuart EA; Hernán MA
    Am J Epidemiol; 2021 Aug; 190(8):1632-1642. PubMed ID: 33324969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095.
    Li L; Eron JJ; Ribaudo H; Gulick RM; Johnson BA
    J Am Stat Assoc; 2012; 107(498):542-554. PubMed ID: 23329858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving causal inference with a doubly robust estimator that combines propensity score stratification and weighting.
    Linden A
    J Eval Clin Pract; 2017 Aug; 23(4):697-702. PubMed ID: 28116816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generalizing randomized trial findings to a target population using complex survey population data.
    Ackerman B; Lesko CR; Siddique J; Susukida R; Stuart EA
    Stat Med; 2021 Feb; 40(5):1101-1120. PubMed ID: 33241607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A note on semiparametric efficient generalization of causal effects from randomized trials to target populations.
    Li F; Hong H; Stuart EA
    Commun Stat Theory Methods; 2023; 52(16):5767-5798. PubMed ID: 37484707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals.
    Dahabreh IJ; Robertson SE; Tchetgen EJ; Stuart EA; Hernán MA
    Biometrics; 2019 Jun; 75(2):685-694. PubMed ID: 30488513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency and robustness of causal effect estimators when noncompliance is measured with error.
    Boatman JA; Vock DM; Koopmeiners JS
    Stat Med; 2018 Dec; 37(28):4126-4141. PubMed ID: 30109713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intervention treatment distributions that depend on the observed treatment process and model double robustness in causal survival analysis.
    Wen L; Marcus JL; Young JG
    Stat Methods Med Res; 2023 Mar; 32(3):509-523. PubMed ID: 36597699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ensemble and calibration multiply robust estimation for quantile treatment effect.
    He X; Wang L
    J Appl Stat; 2022; 49(15):3823-3845. PubMed ID: 36324477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model misspecification and robustness in causal inference: comparing matching with doubly robust estimation.
    Waernbaum I
    Stat Med; 2012 Jul; 31(15):1572-81. PubMed ID: 22359267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust causal inference of drug-drug interactions.
    Shu D; Han P; Hennessy S; Miano TA
    Stat Med; 2023 Mar; 42(7):970-992. PubMed ID: 36627826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratified doubly robust estimators for the average causal effect.
    Hattori S; Henmi M
    Biometrics; 2014 Jun; 70(2):270-7. PubMed ID: 24571129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transporting randomized trial results to estimate counterfactual survival functions in target populations.
    Cao Z; Cho Y; Li F
    Pharm Stat; 2024; 23(4):442-465. PubMed ID: 38233102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.